Abstract
The SARS-CoV-2 pandemic has been characterized by the repeated emergence of genetically distinct virus variants of increased transmissibility and immune evasion compared to pre-existing lineages. In many countries, their containment required the intervention of public health authorities and the imposition of control measures. While the primary role of testing is to identify infection, target treatment, and limit spread (through isolation and contact tracing), a secondary benefit is in terms of surveillance and the early detection of new variants. Here we study the spatial invasion and early spread of the Alpha, Delta, and Omicron (BA.1 and BA.2) variants in England from September 2020 to February 2022 using the random neighbourhood covering (RaNCover) method. This is a statistical technique for the detection of aberrations in spatial point processes, which we tailored here to community PCR (polymerase-chain-reaction) test data where the TaqPath kit provides a proxy measure of the switch between variants. Retrospectively, RaNCover detected the earliest signals associated with the four novel variants that led to large infection waves in England. With suitable data our method therefore has the potential to rapidly detect outbreaks of future SARS-CoV-2 variants, thus helping to inform targeted public health interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, EPSRC, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and the Wellcome Trust (MC, MJK). MJK is was also supported by the JUNIPER modelling consortium [grant number MR/V038613/1] and by the National Institute for Health Research (NIHR) [Policy Research Programme, Mathematical and Economic Modelling for Vaccination and Immunisation Evaluation, and Emergency Response; NIHR200411]. MJK is affiliated to the National Institute for Health Research Health Protection Research Units (NIHR HPRUs) in Gastrointestinal Infections and in Genomics and Enabling Data. MJK is also funded by UK Research and Innovation through the JUNIPER modelling consortium (MR/V038613/1). This research is supported by the National Institute for Health and Care Research (NIHR) Applied Research Collaboration (ARC) West Midlands (DT). The views expressed are those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social Care or Public Health England. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics of the use of these data for these purposes was agreed by the UK Health Security Agency with the Government's SPI-M(O) / SAGE committees.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† m.j.keeling{at}warwick.ac.uk
Methodology and Discussion sections updated for clarity. Typos corrected. Supplementary text updated with one additional figure.
Data Availability
SARS-CoV-2 data were supplied under strict data protection protocols agreed between the researchers and UK Health Protection Agency. Interested readers wanting similar data may wish to contact DataAccess{at}ukhsa.gov.uk, as detailed at https://www.gov.uk/government/publications/accessing-ukhsa-protected-data/accessing-ukhsa-protected-data. Spatial maps created with Sf using digital vector boundaries available from the Office for National Statistics, licensed under Open Government Licence v.3.0. Crown copyright and database right 2022. Terms and conditions of supply for the digital boundaries and reference maps are provided at https://www.ons.gov.uk/methodology/geography/licences. The scripts utilised in this project can be found at the following repository https://github.com/mcavallaro/SARS-CoV-2-spatiotemporal-surveillance.
https://github.com/mcavallaro/SARS-CoV-2-spatiotemporal-surveillance
